头孢他林治疗中性粒细胞减少症的风险:综述

Qasmieh Samah, Ataessien Joelle, House Monique, Zegar Shakib, Brown Tuiana, Davidson Ryan
{"title":"头孢他林治疗中性粒细胞减少症的风险:综述","authors":"Qasmieh Samah, Ataessien Joelle, House Monique, Zegar Shakib, Brown Tuiana, Davidson Ryan","doi":"10.23937/2474-3658/1510305","DOIUrl":null,"url":null,"abstract":"Objective: Ceftaroline is a fifth-generation cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA), which is a clinically distinct feature for a member of this class. Cephalosporins have previously been associated with neutropenia, a serious hematologic condition with an absolute neutrophil count (ANC) falling below 1500-1800 cells/µL. Since its FDA approval in 2010, ceftaroline has been associated with neutropenia in several studies. In this review, our aim is to examine these reports and evaluate their findings. Data sources: A systematic search was conducted using PubMED, Embase, and Web of Science databases. Keywords utilized in the search were “ceftaroline, or Teflaro, or Zinforo” and “neutropenia.” Study selection: Case reports, case series, observational, and experimental studies in the English language of human participants were included. For inclusion, neutropenia was defined as an ANC of no more than 1800 cells/µL. Studies reporting concurrent exposure to chemotherapy were excluded. Data extraction/synthesis: Search results produced eight published articles that underwent review by the authors. Two case studies and six observational studies highlighted a common theme and outcome: Extended use of ceftaroline with exposure greater than two consecutive weeks is associated with an increased risk of neutropenia. Conclusions: To our knowledge, this is the first review to explore the risk of neutropenia with ceftaroline use. Despite the limited amount of relevant published research, existing results suggest a potential association. Large well-designed observational studies are needed to delineate the impact and implications of this serious adverse event.","PeriodicalId":93465,"journal":{"name":"Journal of infectious diseases and epidemiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of Neutropenia with the Use of Ceftaroline: A Review\",\"authors\":\"Qasmieh Samah, Ataessien Joelle, House Monique, Zegar Shakib, Brown Tuiana, Davidson Ryan\",\"doi\":\"10.23937/2474-3658/1510305\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Ceftaroline is a fifth-generation cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA), which is a clinically distinct feature for a member of this class. Cephalosporins have previously been associated with neutropenia, a serious hematologic condition with an absolute neutrophil count (ANC) falling below 1500-1800 cells/µL. Since its FDA approval in 2010, ceftaroline has been associated with neutropenia in several studies. In this review, our aim is to examine these reports and evaluate their findings. Data sources: A systematic search was conducted using PubMED, Embase, and Web of Science databases. Keywords utilized in the search were “ceftaroline, or Teflaro, or Zinforo” and “neutropenia.” Study selection: Case reports, case series, observational, and experimental studies in the English language of human participants were included. For inclusion, neutropenia was defined as an ANC of no more than 1800 cells/µL. Studies reporting concurrent exposure to chemotherapy were excluded. Data extraction/synthesis: Search results produced eight published articles that underwent review by the authors. Two case studies and six observational studies highlighted a common theme and outcome: Extended use of ceftaroline with exposure greater than two consecutive weeks is associated with an increased risk of neutropenia. Conclusions: To our knowledge, this is the first review to explore the risk of neutropenia with ceftaroline use. Despite the limited amount of relevant published research, existing results suggest a potential association. Large well-designed observational studies are needed to delineate the impact and implications of this serious adverse event.\",\"PeriodicalId\":93465,\"journal\":{\"name\":\"Journal of infectious diseases and epidemiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of infectious diseases and epidemiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23937/2474-3658/1510305\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of infectious diseases and epidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23937/2474-3658/1510305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Risk of Neutropenia with the Use of Ceftaroline: A Review
Objective: Ceftaroline is a fifth-generation cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA), which is a clinically distinct feature for a member of this class. Cephalosporins have previously been associated with neutropenia, a serious hematologic condition with an absolute neutrophil count (ANC) falling below 1500-1800 cells/µL. Since its FDA approval in 2010, ceftaroline has been associated with neutropenia in several studies. In this review, our aim is to examine these reports and evaluate their findings. Data sources: A systematic search was conducted using PubMED, Embase, and Web of Science databases. Keywords utilized in the search were “ceftaroline, or Teflaro, or Zinforo” and “neutropenia.” Study selection: Case reports, case series, observational, and experimental studies in the English language of human participants were included. For inclusion, neutropenia was defined as an ANC of no more than 1800 cells/µL. Studies reporting concurrent exposure to chemotherapy were excluded. Data extraction/synthesis: Search results produced eight published articles that underwent review by the authors. Two case studies and six observational studies highlighted a common theme and outcome: Extended use of ceftaroline with exposure greater than two consecutive weeks is associated with an increased risk of neutropenia. Conclusions: To our knowledge, this is the first review to explore the risk of neutropenia with ceftaroline use. Despite the limited amount of relevant published research, existing results suggest a potential association. Large well-designed observational studies are needed to delineate the impact and implications of this serious adverse event.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信